Science
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19 – EurekAlert
This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab…
What The Study Did: This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab vs placebo on change in day 11 severe acute respiratory syndrome coronavirus 2 viral load in patients with mild to moderate COVID-19.
Authors: Daniel M. Skovronsky, M.D., Ph.D., of Eli Lilly and Company in Indianapolis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at…
-
General18 hours agoMore buses without dedicated lanes likely after Gold Coast light rail plan scrapped
-
Business23 hours agoThis artificial intelligence (AI) stock could be the Nvidia of quantum computing
-
Business22 hours agoTesla just offered Elon Musk $1 trillion. Here’s what it could mean for the company.
-
Noosa News20 hours agoStolen truck chase ends in arrest after chaotic three-hour pursuit from Brisbane to Tiaro